Summary
Definition
History and exam
Key diagnostic factors
- decreased libido
- loss of spontaneous morning erections
- erectile dysfunction
- normocytic anaemia
- gynaecomastia
- subfertility
- micropenis
- small testes
- bifid or hypoplastic scrotum
- cryptorchidismespecially if bilateral
- segmental dysproportion
- bitemporal hemianopia
- low trauma fractures
- loss of height
- anosmia
Other diagnostic factors
- decreased energy and fatigue
- absent or incomplete puberty
- scrotal hypoplasiahypopigmentationand absent rugae
- decreased muscle mass and strength
- loss of axillary and pubic hair
- lack of facial hair
- poor concentration and memory
- depressed or labile mood
- sleep disturbance
- hot flushes and sweats
- tall stature
- fine wrinkling of facial skin
Risk factors
- genetic anomaly
- type 2 diabetes mellitus
- use of alkylating agentsopioidsor glucocorticoids
- use of exogenous sex hormones and GnRH analogues
- hyperprolactinaemia
- parasellar tumour or apoplexy of pituitary macroadenoma
- testicular damage
- infection
- varicocele
Diagnostic investigations
1st investigations to order
- serum total testosterone
Investigations to consider
- serum sex hormone-binding globulin (SHBG)
- calculated free testosterone
- serum LH/FSH
- semen analysis
- FBC
- serum prolactin
- serum transferrin saturation and ferritin
- MRI pituitary
- genetic testing
- dual-energy x-ray absorptiometry (DEXA or DXA)
Treatment algorithm
non-gonadal illness
not desiring fertility currently: primary hypogonadism
not desiring fertility currently: secondary hypogonadism
desiring fertility currently: primary hypogonadism
desiring fertility currently: secondary hypogonadism
Contributors
Authors
Richard QuintonMD FRCP(Edin)
Consultant Endocrinologist
Northern Region Gender Dysphoria Service
Tyne & Wear NHS Foundation Trust
Newcastle upon Tyne
UK
Honorary Reader in Reproductive Endocrinology
Department of MetabolismDigestion and Reproduction
Imperial College London
UK
Disclosures
RQ has received speaker fees and an advisory board fee from Besins Healthcare UKspeaker fees from Androlabsand was on an advisory board for Roche Diagnostics. RQ is an author of several references cited in this topic.
Channa N. JayasenaPhD FRCP FRCPath
Consultant and Reader in Reproductive Endocrinology/Andrology
Department of Investigative Medicine
Hammersmith Hospital
Imperial College London
London
UK
Disclosures
CNJ has an investigator-led research grant from LogixX Pharma Ltd. CNJ is supported by a National Institute for Health Research (NIHR) Post-Doctoral Fellowship. CNJ is an author of several references cited in this topic.
Acknowledgements
Dr Richard Quinton and Dr Channa N. Jayasena would like to gratefully acknowledge Dr Charles WelliverDr T. Hugh JonesDr Milena Braga-Basariaand Dr Shehzad Basariaprevious contributors to this topic.
Disclosures
CW has worked as a consultant for Coloplastand as an investigator for Auxilium PharmaceuticalsMereo BioPharmaPROCEPT BioRoboticsand Repros; and he is a paid reviewer at Oakstone Publishing and BMJ Best Practice. CW also has a family member who is an employee at Bristol-Myers Squibb. THJ and SB are authors of references cited in this topic. MB declared that she had no competing interests.
Peer reviewers
Randal J. UrbanMD
Professor
Department of Internal Medicine
University of Texas Medical Branch
Galveston
TX
Disclosures
RJU declares that he has no competing interests.
Niki KaravitakiMBBSMScPhD
Consultant Endocrinologist
Oxford Centre for DiabetesEndocrinology and Metabolism
Churchill Hospital
Oxford
UK
Disclosures
NK declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
Mulhall JPTrost LWBrannigan REet al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018 Aug;200(2):423-32.Full text Abstract
Jayasena CNAnderson RALlahana Set al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf). 2022 Feb;96(2):200-19.Full text Abstract
Matsumoto AM. Diagnosis and evaluation of hypogonadism. Endocrinol Metab Clin North Am. 2022 Mar;51(1):47-62. Abstract
Bhasin SBrito JPCunningham GRet al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-44.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Klinefelter syndrome
- Pituitary macroadenoma
- Prolactinoma
More DifferentialsGuidelines
- Guidelines for testosterone replacement therapy in male hypogonadism
- Fertility problems: assessment and treatment
More GuidelinesPatient information
Erection problems
Fertility problems: some reasons
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer
